Apimeds Pharmaceuticals US, Inc. (APUS)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

5.02 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Net income

$6.00M

Free cash flow

$8.98M

Return on equity

-3.9%

Return on capital

-6.1%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
14 May 2025	Kim Christopher Chairman and CMO	Bought	$14.38K	39.1%
13 May 2025	Kim Christopher Chairman and CMO	Bought	$35.98K	opened
12 May 2025	Inscobee Inc. 10% owner	Bought	$2.00M	33.7%
12 May 2025	Koo Jakap Director	Bought	$56.72K	4.6%

33out of 100

Profitability 0

Financial strength 60

Growth n/a

Insiders 50

Strongest on financial strength (60), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan